A drug called imeglimin restored muscle mass and strength in mice with fatty liver disease and muscle wasting, while also improving liver health and fixing damaged cellular energy factories. According to Gram Research analysis, the drug preserved muscle fiber size, reactivated growth signals in muscle cells, and reduced liver inflammation and fat buildup without changing blood sugar levels. These findings suggest imeglimin could become a treatment for people with both conditions, though human studies are still needed.
Researchers tested a drug called imeglimin on mice with a condition where fat builds up in the liver and muscles waste away. According to Gram Research analysis, the drug helped restore muscle strength and mass while also improving liver health. The treatment worked by fixing broken energy-producing structures inside cells and reducing inflammation. These findings suggest imeglimin could become a new treatment option for people suffering from both fatty liver disease and muscle loss, though human studies are still needed to confirm these results.
Key Statistics
A 2026 experimental study in mice found that imeglimin preserved muscle grip strength and muscle fiber diameter in animals with fatty liver disease and muscle wasting, while simultaneously reducing liver fat accumulation and inflammation.
Research published in 2026 showed that imeglimin restored mitochondrial complex I and IV activities and increased NAD+ levels in muscle tissue, indicating improved cellular energy production in mice with MASH-associated sarcopenia.
A 2026 study demonstrated that imeglimin reactivated the AKT-mTOR signaling pathway, the cellular growth system, while suppressing genes that trigger muscle breakdown including Fbxo32, Trim63, and Mstn in diseased mice.
In 2026 research, imeglimin improved autophagy-lysosome homeostasis by increasing the LC3-II to LC3-I ratio and reducing p62 accumulation, indicating enhanced cellular cleanup in muscle tissue of mice with fatty liver disease.
The Quick Take
- What they studied: Whether a diabetes drug called imeglimin could help mice with fatty liver disease and muscle wasting by fixing damaged mitochondria, the tiny energy factories inside cells.
- Who participated: 40 laboratory mice divided into four groups, all fed a special diet designed to create fatty liver disease and muscle loss similar to what happens in humans.
- Key finding: Imeglimin preserved muscle mass and grip strength while reducing liver inflammation and fat buildup. The drug restored muscle fiber size and reactivated cellular growth signals without changing blood sugar or insulin levels.
- What it means for you: This research suggests imeglimin could potentially treat people with both fatty liver disease and muscle loss, but human clinical trials are needed before it becomes available as a treatment. The findings are promising but not yet proven in people.
The Research Details
Scientists created a disease model in mice by feeding them a special diet lacking choline and high in fat for six weeks. This diet causes the same combination of problems seen in people: fatty liver disease and muscle wasting. After six weeks, researchers gave half the mice imeglimin, a drug originally developed to help with diabetes, twice daily for another six weeks. The other mice received no treatment and served as a comparison group.
Researchers then examined the mice’s muscles and livers in detail. They looked at muscle strength using grip tests, measured muscle fiber size under a microscope, and analyzed the health of mitochondria, the energy-producing structures inside cells. They also studied the molecular signals that tell cells to build muscle or break it down. Additionally, they tested the drug directly on muscle cells grown in laboratory dishes to understand exactly how it works.
This approach allowed scientists to see both the overall effects of the drug on the whole animal and the specific cellular mechanisms that made it work.
This research design is important because it combines whole-animal studies with detailed cellular analysis. By testing imeglimin in living mice, researchers could see how the drug affects the complex interactions between the liver and muscles. By also testing it on isolated muscle cells, they could identify the exact molecular pathways involved. This two-pronged approach provides strong evidence for how and why the drug works.
The study used a controlled experimental design with comparison groups, which strengthens the reliability of the findings. The researchers measured multiple outcomes, including muscle strength, muscle size, liver health, mitochondrial function, and molecular signaling pathways. They also confirmed their findings using both living animals and laboratory cell cultures. However, this is animal research, so results may not directly translate to humans. The study was published in a peer-reviewed scientific journal, indicating it underwent expert review.
What the Results Show
Imeglimin successfully preserved muscle mass and strength in mice with fatty liver disease and muscle wasting. Mice treated with the drug maintained normal grip strength and larger muscle fiber diameter compared to untreated mice. The drug also reduced the expression of genes that trigger muscle breakdown, including Fbxo32, Trim63, and Mstn. Additionally, imeglimin reactivated the AKT-mTOR signaling pathway, which is the cellular system that tells muscles to grow and repair themselves.
The drug also improved liver health significantly. It reduced fat accumulation in the liver, decreased inflammation, lowered oxidative stress (cellular damage from unstable molecules), and reduced scarring. Importantly, imeglimin restored insulin-like growth factor-1, a hormone that promotes muscle growth, both in the liver and in the bloodstream. These improvements occurred without changing fasting blood sugar or insulin levels, suggesting the drug works through a different mechanism than typical diabetes medications.
At the cellular level, imeglimin restored the function of mitochondria, the energy factories inside cells. The drug increased mitochondrial biogenesis, meaning cells made more mitochondria. It also improved the activity of mitochondrial complexes I and IV, which are the machinery that produces cellular energy. The drug restored NAD+ levels, a critical molecule for cellular energy production and metabolism.
Imeglimin improved autophagy-lysosome homeostasis, which is the cellular cleanup system that removes damaged proteins and organelles. The drug increased the LC3-II to LC3-I ratio and reduced p62 accumulation, both markers of improved cellular recycling. This is important because proper cellular cleanup prevents the buildup of damaged components that contribute to muscle wasting. The drug also reduced intramuscular inflammation and oxidative stress, creating a healthier environment for muscle cells. When tested directly on muscle cells stimulated with interleukin-6, a pro-inflammatory molecule, imeglimin restored muscle cell diameter, mitochondrial function, and suppressed genes that trigger muscle breakdown.
This research builds on existing knowledge that mitochondrial dysfunction and inflammation drive muscle loss in fatty liver disease. Previous studies identified that problems with cellular energy production and excessive protein breakdown contribute to sarcopenia, or muscle wasting. This study is novel because it demonstrates that imeglimin, a mitochondrial-targeting drug, can simultaneously improve both liver function and muscle health. The dual benefit is significant because most previous treatments focused on either the liver or the muscles, not both. The finding that imeglimin works without changing blood sugar levels suggests a new therapeutic approach distinct from conventional diabetes medications.
This study used laboratory mice, not humans, so results may not directly translate to people. The specific diet used to create the disease model may not perfectly replicate the human condition. The study did not examine long-term effects beyond the 12-week treatment period. Researchers did not test different doses or treatment durations to determine optimal dosing for humans. The study also did not examine potential side effects or drug interactions that might occur in people. Finally, the sample size of 40 mice is relatively small, though appropriate for initial mechanistic studies.
The Bottom Line
Based on this research, imeglimin shows strong promise as a potential treatment for people with both fatty liver disease and muscle loss. However, human clinical trials are necessary before any recommendations can be made for patient use. People currently experiencing muscle loss and fatty liver disease should discuss treatment options with their healthcare provider. This research suggests imeglimin warrants further investigation as a therapeutic candidate, but it is not yet approved or recommended for human use.
This research is most relevant to people with metabolic dysfunction-associated steatohepatitis (MASH), previously called NASH, who also experience muscle wasting. It may also interest people with type 2 diabetes, since imeglimin is an antidiabetic drug. Healthcare providers treating fatty liver disease and muscle loss should monitor developments in imeglimin research. Researchers studying mitochondrial dysfunction and muscle wasting will find these findings particularly valuable. People without these conditions do not need to take action based on this research.
In this mouse study, benefits appeared after six weeks of treatment. If imeglimin moves to human trials, it typically takes several years to establish safety and effectiveness. Even if human trials are successful, regulatory approval could take additional years. Realistic expectations would be that any new treatment based on this research would not be available to patients for at least 5 to 10 years.
Frequently Asked Questions
What is imeglimin and how does it help with muscle loss?
Imeglimin is a diabetes drug that targets mitochondria, the energy-producing structures inside cells. Research shows it restores mitochondrial function, reduces inflammation, and reactivates cellular growth signals that tell muscles to build and repair themselves, preventing muscle wasting.
Can I take imeglimin now if I have fatty liver disease and muscle loss?
Imeglimin is not yet approved for treating fatty liver disease or muscle loss in humans. This research was conducted in mice. You should discuss treatment options with your healthcare provider, who can recommend currently available therapies while imeglimin undergoes human clinical trials.
How long does it take for imeglimin to work based on this research?
In this mouse study, benefits appeared after six weeks of treatment. If imeglimin advances to human trials and eventually becomes approved, realistic timelines for seeing benefits would likely be measured in weeks to months, but human studies are needed to confirm this.
Does imeglimin affect blood sugar levels?
In this mouse study, imeglimin improved muscle and liver health without changing fasting blood sugar or insulin levels. This suggests it works through a different mechanism than typical diabetes drugs, though human studies are needed to confirm this finding in people.
Why is fixing mitochondria important for muscle loss?
Mitochondria produce the energy cells need to function and grow. When mitochondria are damaged, muscle cells cannot generate enough energy to maintain their size and strength. Imeglimin restores mitochondrial function, allowing muscle cells to produce energy and resist breakdown.
Want to Apply This Research?
- Track grip strength weekly using a hand dynamometer if available, or monitor ability to perform daily activities requiring hand strength like opening jars or carrying groceries. Record measurements in the app to visualize trends over time.
- Users could log daily activities that require muscle strength and endurance, such as climbing stairs, walking distance, or resistance exercises. The app could provide reminders to perform these activities consistently and track improvements in performance as a proxy for muscle health.
- Establish a baseline measurement of muscle-related activities at the start of any treatment. Set monthly check-ins to reassess grip strength, walking distance, or other functional measures. Use the app to create a visual trend line showing improvements or declines over 3 to 6 month periods, which can be shared with healthcare providers.
This research was conducted in laboratory mice and has not been tested in humans. Imeglimin is not currently approved for treating fatty liver disease or muscle loss. These findings are preliminary and should not be interpreted as medical advice or recommendations for treatment. Anyone with fatty liver disease or muscle wasting should consult with a qualified healthcare provider about appropriate treatment options. Do not start, stop, or change any medications without medical supervision. This article is for educational purposes only and does not replace professional medical guidance.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.